Status | Study |
Recruiting |
Study Name: Respiratory Muscle Training in L-Onset Pompe Disease (LOPD) Condition: Glycogen Storage Disease Type II Date: 2016-06-13 Interventions: Device: RMT therapy using modified RMT device |
Recruiting |
Study Name: A Pilot Study of Pyridostigmine in Pompe Disease Condition: Pompe Disease Date: 2015-01-23 Interventions: Drug: Pyridostigmine Bromide Pyridostigmine is an acetylcholinesterase inhibitor, which increases the am |
Recruiting |
Study Name: Response to Diaphragmatic Pacing in Subjects With Pompe Disease Condition: Pompe Disease Date: 2015-01-21 Interventions: Other: Pulmonary function testing |
Recruiting |
Study Name: NeoGAA Extension Study Condition: Glycogen Storage Disease Type II Pompe Disease Date: 2013-12-04 Interventions: Drug: GZ402666 Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration |
Completed |
Study Name: Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy Condition: Pompe Disease Date: 2013-09-11 Interventions: Drug: Clenbuterol Drug: Placebo |
Recruiting |
Study Name: A Natural History Study of Adult Onset Pompe Disease Using Muscle MRI Condition: Pompe Disease Date: 2013-07-31 |
Completed |
Study Name: Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy Condition: Pompe Disease Date: 2013-06-21 Interventions: Drug: Albuterol Initially 4 mg |
Completed |
Study Name: Albuterol in Individuals With Late Onset Pompe Disease (LOPD) Condition: Pompe Disease Date: 2013-05-08 Interventions: Drug: Albuterol Albuterol 4 mg |
Withdrawn |
Study Name: High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease Condition: Glycogen Storage Disease Type II Date: 2012-08-01 Interventions: Other: High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding |
Recruiting |
Study Name: Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease Condition: Pompe Disease (Late-Onset) Glycogen Stora Date: 2011-08-02 Interventions: Biological: alglucosidase alfa Intravenous (IV) infusion of 20mg/kg body weight every other week (qow) |